Pharma Tech

SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race

Aug 27, 2026, 1:40 PM

Read Full Article → SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race

Translate article text

Choose a language and wait for the translated text.

SK and Biohaven hope opakalim will show differential benefit to Xenon’s rival focal epilepsy drug, azetukalner, in an upcoming pivotal readout.